Alzheimer's Assocation Research only
All of
  • Go to
  • Research Center
  • AAIC
  • Journal
  • Grants
  • TrialMatch
  • Press
  • Donate
  • Contact Us
Science and Progress
Clinical Trials
Funding and Collaboration
You can Help
Stay Current
Video and Resources

Text Size

Small text Medium text Large text

Research Grants 2012

To view an abstract, select an author from the vertical list on the left.

2012 Grants - Gil-Bea

Pharmacological Manipulation of BDNF as Therapeutic Challenge for Alzheimer's Disease

Francisco J. Gil-Bea, Ph.D.
Foundation for Applied Medical Research
Pamplona, Spain

2012 New Investigator Research Grant

In recent years, much Alzheimer's disease research has focused on developing drug therapies that target the disease's biomarkers, including the protein fragment beta-amyloid. Many of these treatments, however, have not yet achieved satisfactory results in clinical trials. In response, some investigators have been exploring other therapeutic strategies for Alzheimer's. Such approaches often focus on helping moderate cognitive decline in people who already have the disease.

Francisco J. Gil-Bea, Ph.D., and colleagues have been studying the therapeutic potential of brain-derived neurotrophic factor (BDNF). This protein occurs naturally in the brain, and it has been shown to prevent nerve cell death, promote the growth of new neurons, and facilitate the development of synapses (the tiny channels through which brain cells send and receive chemical messages). Thus BDNF is important for maintaining proper cell-to-cell communication in the brain and in maintaining cognitive health. Not surprisingly, people with Alzheimer's disease possess reduced levels of this protein. Yet BDNF-related therapies have proven unsuccessful. Because the protein is too large to cross the blood-brain barrier, which protects the brain from foreign substances in the blood, it cannot be delivered to the brain easily. Moreover, treatments that involve large doses of BDNF have caused harmful side effects in animals. In an attempt to develop a safer and more practical BDNF treatment, Dr. Gil-bea and colleagues have found that by boosting the activity of a brain protein called tissue-plasminogen activator (tPA), they could increase BDNF levels in cultured cells. This treatment also made the cells less vulnerable to the toxicity of beta-amyloid and other Alzheimer's-related molecules.

For their current project, the researchers plan to test their tPA/BDNF treatment in mice engineered to develop Alzheimer's-like symptoms. They also plan to identify other mechanisms that may promote BDNF levels in cells and living animals. The results of this work could lead to novel methods for helping people with Alzheimer's cope with their disease.

Alzheimer's Association International Conference | July 16-20, 2017, London, England

Abstract Submissions Now Open

The Scientific Program Committee is now accepting submissions for poster
presentations, oral presentations and featured research sessions.